Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 4
1992 2
1993 3
1994 3
1995 4
1996 4
1997 8
1998 4
1999 3
2000 4
2001 2
2002 4
2003 6
2004 6
2005 4
2006 8
2007 7
2008 11
2009 7
2010 10
2011 7
2012 9
2013 10
2014 11
2015 12
2016 12
2017 8
2018 19
2019 11
2020 9
2021 28
2022 12
2023 18
2024 22
2025 26
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Results by year

Filters applied: . Clear all
Page 1
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: mackensen a. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Mackensen A, et al. Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15. Nat Med. 2022. PMID: 36109639
CAR T-cell therapy in autoimmune diseases.
Schett G, Mackensen A, Mougiakakos D. Schett G, et al. Among authors: mackensen a. Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22. Lancet. 2023. PMID: 37748491 Review.
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series.
Auth J, Müller F, Völkl S, Bayerl N, Distler JHW, Tur C, Raimondo MG, Chenguiti Fakhouri S, Atzinger A, Coppers B, Eckstein M, Liphardt AM, Bäuerle T, Tascilar K, Aigner M, Kretschmann S, Wirsching A, Taubmann J, Hagen M, Györfi AH, Kharboutli S, Krickau T, Dees C, Spörl S, Rothe T, Harrer T, Bozec A, Grieshaber-Bouyer R, Fuchs F, Kuwert T, Berking C, Horch RE, Uder M, Mackensen A, Schett G, Bergmann C. Auth J, et al. Among authors: mackensen a. Lancet Rheumatol. 2025 Feb;7(2):e83-e93. doi: 10.1016/S2665-9913(24)00282-0. Epub 2024 Nov 11. Lancet Rheumatol. 2025. PMID: 39542003 Free article.
Advancements and challenges in CAR T cell therapy in autoimmune diseases.
Schett G, Müller F, Taubmann J, Mackensen A, Wang W, Furie RA, Gold R, Haghikia A, Merkel PA, Caricchio R, D'Agostino MA, Locatelli F, June CH, Mougiakakos D. Schett G, et al. Among authors: mackensen a. Nat Rev Rheumatol. 2024 Sep;20(9):531-544. doi: 10.1038/s41584-024-01139-z. Epub 2024 Aug 6. Nat Rev Rheumatol. 2024. PMID: 39107407 Review.
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G. Mougiakakos D, et al. Among authors: mackensen a. N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725. N Engl J Med. 2021. PMID: 34347960 No abstract available.
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells.
Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M, Kretschmann S, Reimann H, Harrer T, Bayerl N, Boeltz S, Wirsching A, Taubmann J, Rösler W, Spriewald B, Wacker J, Atzinger A, Uder M, Kuwert T, Mackensen A, Schett G. Bergmann C, et al. Among authors: mackensen a. Ann Rheum Dis. 2023 Aug;82(8):1117-1120. doi: 10.1136/ard-2023-223952. Epub 2023 May 5. Ann Rheum Dis. 2023. PMID: 37147112 Free PMC article. No abstract available.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain MD, Subklewe M. Rejeski K, et al. Among authors: mackensen a. Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543. Blood. 2021. PMID: 34166502 Free PMC article.
CD19-CAR T-cell therapy induces deep tissue depletion of B cells.
Tur C, Eckstein M, Velden J, Rauber S, Bergmann C, Auth J, Bucci L, Corte G, Hagen M, Wirsching A, Grieshaber-Bouyer R, Reis P, Kittan N, Wacker J, Rius Rigau A, Ramming A, D'Agostino MA, Hartmann A, Müller F, Mackensen A, Bozec A, Schett G, Raimondo MG. Tur C, et al. Among authors: mackensen a. Ann Rheum Dis. 2025 Jan;84(1):106-114. doi: 10.1136/ard-2024-226142. Epub 2025 Jan 2. Ann Rheum Dis. 2025. PMID: 39874224
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.
Müller F, Wirsching A, Hagen M, Völkl S, Tur C, Raimondo MG, Taubmann J, Bucci L, Zhang L, Kretschmann S, Aigner M, Eckstein M, Spörl S, Kharboutli S, Böltz S, Atzinger A, Munoz L, Schett G, Mackensen A, Grieshaber-Bouyer R. Müller F, et al. Among authors: mackensen a. Nat Med. 2025 Jun;31(6):1793-1797. doi: 10.1038/s41591-025-03718-3. Epub 2025 Apr 17. Nat Med. 2025. PMID: 40245922 Free PMC article.
295 results